Annual EBITDA:
$12.81M+$129.14M(+111.01%)Summary
- As of today, BCRX annual EBITDA is $12.81 million, with the most recent change of +$129.14 million (+111.01%) on December 31, 2024.
- During the last 3 years, BCRX annual EBITDA has risen by +$134.55 million (+110.52%).
- BCRX annual EBITDA is now at all-time high.
Performance
BCRX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$29.93M-$189.00K(-0.63%)Summary
- As of today, BCRX quarterly EBITDA is $29.93 million, with the most recent change of -$189.00 thousand (-0.63%) on September 30, 2025.
- Over the past year, BCRX quarterly EBITDA has increased by +$21.92 million (+273.93%).
- BCRX quarterly EBITDA is now -0.63% below its all-time high of $30.11 million, reached on June 30, 2025.
Performance
BCRX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$77.40M+$21.92M(+39.52%)Summary
- As of today, BCRX TTM EBITDA is $77.40 million, with the most recent change of +$21.92 million (+39.52%) on September 30, 2025.
- Over the past year, BCRX TTM EBITDA has increased by +$116.75 million (+296.72%).
- BCRX TTM EBITDA is now at all-time high.
Performance
BCRX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
BCRX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +111.0% | +273.9% | +296.7% |
| 3Y3 Years | +110.5% | +275.5% | +150.6% |
| 5Y5 Years | +113.3% | +170.1% | +163.6% |
BCRX EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +108.9% | -0.6% | +165.2% | at high | +150.6% |
| 5Y | 5-Year | at high | +107.6% | -0.6% | +157.5% | at high | +142.9% |
| All-Time | All-Time | at high | +107.6% | -0.6% | +157.5% | at high | +142.9% |
BCRX EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2025 | - | $29.93M(-0.6%) | $77.40M(+39.5%) |
| Jun 2025 | - | $30.11M(+39.7%) | $55.48M(+61.1%) |
| Mar 2025 | - | $21.56M(+613.4%) | $34.44M(+2755.6%) |
| Dec 2024 | $12.81M(+111.0%) | -$4.20M(-152.5%) | -$1.30M(+96.7%) |
| Sep 2024 | - | $8.00M(-11.9%) | -$39.34M(+33.1%) |
| Jun 2024 | - | $9.08M(+164.0%) | -$58.85M(+33.3%) |
| Mar 2024 | - | -$14.18M(+66.4%) | -$88.23M(+13.5%) |
| Dec 2023 | -$116.33M(+19.1%) | -$42.25M(-267.3%) | -$102.05M(+3.5%) |
| Sep 2023 | - | -$11.50M(+43.3%) | -$105.72M(+5.0%) |
| Jun 2023 | - | -$20.30M(+27.5%) | -$111.28M(+11.2%) |
| Mar 2023 | - | -$28.01M(+39.0%) | -$125.37M(+14.7%) |
| Dec 2022 | -$143.85M(-18.2%) | -$45.91M(-169.2%) | -$147.00M(+4.0%) |
| Sep 2022 | - | -$17.06M(+50.4%) | -$153.09M(+15.1%) |
| Jun 2022 | - | -$34.39M(+30.7%) | -$180.39M(-2.9%) |
| Mar 2022 | - | -$49.64M(+4.5%) | -$175.38M(+0.9%) |
| Dec 2021 | -$121.74M(+27.3%) | -$52.01M(-17.2%) | -$176.94M(-2.8%) |
| Sep 2021 | - | -$44.35M(-51.0%) | -$172.14M(-1.0%) |
| Jun 2021 | - | -$29.38M(+42.6%) | -$170.48M(+5.0%) |
| Mar 2021 | - | -$51.20M(-8.5%) | -$179.42M(-6.2%) |
| Dec 2020 | -$167.56M(-74.0%) | -$47.20M(-10.5%) | -$168.98M(-38.8%) |
| Sep 2020 | - | -$42.70M(-11.4%) | -$121.71M(-6.8%) |
| Jun 2020 | - | -$38.33M(+6.0%) | -$113.93M(-3.3%) |
| Mar 2020 | - | -$40.76M(>-9900.0%) | -$110.34M(-11.8%) |
| Dec 2019 | -$96.28M(-5.4%) | $76.00K(+100.2%) | -$98.73M(+20.3%) |
| Sep 2019 | - | -$34.92M(-0.5%) | -$123.87M(-5.6%) |
| Jun 2019 | - | -$34.74M(-19.2%) | -$117.25M(-16.6%) |
| Mar 2019 | - | -$29.15M(-16.3%) | -$100.58M(-7.6%) |
| Dec 2018 | -$91.31M(-61.6%) | -$25.06M(+11.4%) | -$93.45M(-8.6%) |
| Sep 2018 | - | -$28.30M(-56.7%) | -$86.06M(-21.3%) |
| Jun 2018 | - | -$18.06M(+18.0%) | -$70.94M(-4.0%) |
| Mar 2018 | - | -$22.03M(-24.6%) | -$68.22M(-20.3%) |
| Dec 2017 | -$56.51M(-17.3%) | -$17.68M(-34.2%) | -$56.71M(-20.5%) |
| Sep 2017 | - | -$13.17M(+14.2%) | -$47.04M(-9.6%) |
| Jun 2017 | - | -$15.34M(-46.0%) | -$42.94M(-8.3%) |
| Mar 2017 | - | -$10.51M(-31.2%) | -$39.64M(+17.6%) |
| Dec 2016 | -$48.17M(-28.0%) | -$8.02M(+11.6%) | -$48.12M(-20.0%) |
| Sep 2016 | - | -$9.07M(+24.7%) | -$40.11M(+9.2%) |
| Jun 2016 | - | -$12.04M(+36.6%) | -$44.16M(-65.2%) |
| Mar 2016 | - | -$19.00M(-44.8%) | -$26.73M(+28.2%) |
| Dec 2015 | -$37.64M(+5.9%) | - | - |
| Sep 2015 | - | -$13.12M(-343.4%) | -$37.23M(-4.3%) |
| Jun 2015 | - | $5.39M(+137.5%) | -$35.68M(+32.2%) |
| Mar 2015 | - | -$14.38M(+4.8%) | -$52.65M(-15.5%) |
| Dec 2014 | -$40.01M(-59.9%) | -$15.12M(-30.6%) | -$45.59M(-24.0%) |
| Sep 2014 | - | -$11.57M(+0.0%) | -$36.76M(-14.7%) |
| Jun 2014 | - | -$11.57M(-57.8%) | -$32.05M(+1.5%) |
| Mar 2014 | - | -$7.33M(-16.8%) | -$32.53M(-7.0%) |
| Dec 2013 | -$25.03M(+25.9%) | -$6.28M(+8.5%) | -$30.41M(+7.6%) |
| Sep 2013 | - | -$6.86M(+43.1%) | -$32.91M(+3.0%) |
| Jun 2013 | - | -$12.06M(-131.0%) | -$33.92M(-6.4%) |
| Mar 2013 | - | -$5.22M(+40.5%) | -$31.89M(-1.2%) |
| Dec 2012 | -$33.79M(+35.4%) | -$8.77M(-11.3%) | -$31.50M(+6.0%) |
| Sep 2012 | - | -$7.88M(+21.3%) | -$33.52M(+12.4%) |
| Jun 2012 | - | -$10.02M(-107.3%) | -$38.26M(+9.5%) |
| Mar 2012 | - | -$4.83M(+55.2%) | -$42.26M(+13.2%) |
| Dec 2011 | -$52.29M(-65.5%) | -$10.79M(+14.5%) | -$48.70M(-6.0%) |
| Sep 2011 | - | -$12.62M(+10.0%) | -$45.94M(-4.4%) |
| Jun 2011 | - | -$14.02M(-24.4%) | -$44.00M(-10.3%) |
| Mar 2011 | - | -$11.27M(-40.6%) | -$39.91M(-28.9%) |
| Dec 2010 | -$31.59M(-160.5%) | -$8.02M(+24.9%) | -$30.97M(-314.5%) |
| Sep 2010 | - | -$10.68M(-7.6%) | -$7.47M(-5.3%) |
| Jun 2010 | - | -$9.93M(-324.8%) | -$7.09M(-29.3%) |
| Mar 2010 | - | -$2.34M(-115.1%) | -$5.49M(+54.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2009 | -$12.12M(+52.5%) | $15.48M(+250.3%) | -$12.13M(+30.1%) |
| Sep 2009 | - | -$10.30M(-23.7%) | -$17.34M(-7.0%) |
| Jun 2009 | - | -$8.33M(+7.3%) | -$16.20M(+22.4%) |
| Mar 2009 | - | -$8.98M(-187.4%) | -$20.87M(+18.3%) |
| Dec 2008 | -$25.54M(+17.4%) | $10.27M(+212.0%) | -$25.54M(+34.8%) |
| Sep 2008 | - | -$9.17M(+29.5%) | -$39.18M(+5.8%) |
| Jun 2008 | - | -$13.00M(+4.7%) | -$41.60M(-15.7%) |
| Mar 2008 | - | -$13.64M(-303.9%) | -$35.95M(-14.2%) |
| Dec 2007 | -$30.91M(+33.1%) | -$3.38M(+70.8%) | -$31.48M(+18.6%) |
| Sep 2007 | - | -$11.59M(-57.9%) | -$38.66M(+10.8%) |
| Jun 2007 | - | -$7.34M(+20.0%) | -$43.37M(+7.4%) |
| Mar 2007 | - | -$9.18M(+13.1%) | -$46.82M(-1.3%) |
| Dec 2006 | -$46.17M(-75.5%) | -$10.56M(+35.2%) | -$46.21M(-7.6%) |
| Sep 2006 | - | -$16.29M(-50.9%) | -$42.94M(-25.0%) |
| Jun 2006 | - | -$10.80M(-26.1%) | -$34.36M(-17.4%) |
| Mar 2006 | - | -$8.56M(-17.4%) | -$29.28M(-11.2%) |
| Dec 2005 | -$26.31M(-26.5%) | -$7.29M(+5.5%) | -$26.32M(-8.9%) |
| Sep 2005 | - | -$7.71M(-34.9%) | -$24.16M(-11.5%) |
| Jun 2005 | - | -$5.71M(-1.9%) | -$21.66M(-4.3%) |
| Mar 2005 | - | -$5.61M(-9.2%) | -$20.76M(-1.0%) |
| Dec 2004 | -$20.79M(-65.3%) | -$5.13M(+1.5%) | -$20.56M(-5.9%) |
| Sep 2004 | - | -$5.21M(-8.2%) | -$19.41M(-10.4%) |
| Jun 2004 | - | -$4.81M(+10.8%) | -$17.57M(-9.9%) |
| Mar 2004 | - | -$5.40M(-35.6%) | -$15.98M(-19.5%) |
| Dec 2003 | -$12.58M(+27.9%) | -$3.98M(-18.0%) | -$13.37M(-13.2%) |
| Sep 2003 | - | -$3.38M(-4.7%) | -$11.81M(+1.2%) |
| Jun 2003 | - | -$3.22M(-15.5%) | -$11.95M(+12.3%) |
| Mar 2003 | - | -$2.79M(-15.5%) | -$13.63M(+18.4%) |
| Dec 2002 | -$17.46M(-343.5%) | -$2.42M(+31.2%) | -$16.71M(-19.4%) |
| Sep 2002 | - | -$3.52M(+28.3%) | -$13.99M(-33.0%) |
| Jun 2002 | - | -$4.91M(+16.4%) | -$10.52M(-98.1%) |
| Mar 2002 | - | -$5.87M(-2062.5%) | -$5.31M(-199.2%) |
| Dec 2001 | -$3.94M(+57.0%) | $299.00K(+710.2%) | -$1.78M(+52.7%) |
| Sep 2001 | - | -$49.00K(-116.1%) | -$3.76M(+39.5%) |
| Jun 2001 | - | $305.00K(+113.1%) | -$6.21M(+34.2%) |
| Mar 2001 | - | -$2.33M(-38.7%) | -$9.44M(-52.9%) |
| Dec 2000 | -$9.16M(-20.6%) | -$1.68M(+32.8%) | -$6.17M(-42.0%) |
| Sep 2000 | - | -$2.50M(+14.5%) | -$4.35M(-3.3%) |
| Jun 2000 | - | -$2.93M(-412.4%) | -$4.21M(-145.6%) |
| Mar 2000 | - | $937.20K(+543.7%) | -$1.71M(+67.3%) |
| Dec 1999 | -$7.60M(-38.2%) | $145.60K(+106.2%) | -$5.25M(+34.3%) |
| Sep 1999 | - | -$2.36M(-445.2%) | -$7.98M(-180.3%) |
| Jun 1999 | - | -$433.40K(+83.3%) | -$2.85M(+45.7%) |
| Mar 1999 | - | -$2.60M(-0.3%) | -$5.24M(+4.6%) |
| Dec 1998 | -$5.50M(+53.0%) | -$2.59M(-193.4%) | -$5.50M(+11.4%) |
| Sep 1998 | - | $2.77M(+198.1%) | -$6.21M(+46.4%) |
| Jun 1998 | - | -$2.83M(+0.9%) | -$11.58M(-4.8%) |
| Mar 1998 | - | -$2.85M(+13.6%) | -$11.05M(+4.7%) |
| Dec 1997 | -$11.70M(-42.7%) | -$3.30M(-26.9%) | -$11.60M(-1.8%) |
| Sep 1997 | - | -$2.60M(-13.0%) | -$11.40M(-2.7%) |
| Jun 1997 | - | -$2.30M(+32.4%) | -$11.10M(-12.1%) |
| Mar 1997 | - | -$3.40M(-9.7%) | -$9.90M(-19.3%) |
| Dec 1996 | -$8.20M(+3.5%) | -$3.10M(-34.8%) | -$8.30M(-13.7%) |
| Sep 1996 | - | -$2.30M(-109.1%) | -$7.30M(-4.3%) |
| Jun 1996 | - | -$1.10M(+38.9%) | -$7.00M(+6.7%) |
| Mar 1996 | - | -$1.80M(+14.3%) | -$7.50M(+10.7%) |
| Dec 1995 | -$8.50M(-37.1%) | -$2.10M(-5.0%) | -$8.40M(-3.7%) |
| Sep 1995 | - | -$2.00M(-25.0%) | -$8.10M(-6.6%) |
| Jun 1995 | - | -$1.60M(+40.7%) | -$7.60M(+1.3%) |
| Mar 1995 | - | -$2.70M(-50.0%) | -$7.70M(-22.2%) |
| Dec 1994 | -$6.20M | -$1.80M(-20.0%) | -$6.30M(-40.0%) |
| Sep 1994 | - | -$1.50M(+11.8%) | -$4.50M(-50.0%) |
| Jun 1994 | - | -$1.70M(-30.8%) | -$3.00M(-130.8%) |
| Mar 1994 | - | -$1.30M | -$1.30M |
FAQ
- What is BioCryst Pharmaceuticals, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for BioCryst Pharmaceuticals, Inc.?
- What is BioCryst Pharmaceuticals, Inc. annual EBITDA year-on-year change?
- What is BioCryst Pharmaceuticals, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for BioCryst Pharmaceuticals, Inc.?
- What is BioCryst Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
- What is BioCryst Pharmaceuticals, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for BioCryst Pharmaceuticals, Inc.?
- What is BioCryst Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
What is BioCryst Pharmaceuticals, Inc. annual EBITDA?
The current annual EBITDA of BCRX is $12.81M
What is the all-time high annual EBITDA for BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals, Inc. all-time high annual EBITDA is $12.81M
What is BioCryst Pharmaceuticals, Inc. annual EBITDA year-on-year change?
Over the past year, BCRX annual EBITDA has changed by +$129.14M (+111.01%)
What is BioCryst Pharmaceuticals, Inc. quarterly EBITDA?
The current quarterly EBITDA of BCRX is $29.93M
What is the all-time high quarterly EBITDA for BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals, Inc. all-time high quarterly EBITDA is $30.11M
What is BioCryst Pharmaceuticals, Inc. quarterly EBITDA year-on-year change?
Over the past year, BCRX quarterly EBITDA has changed by +$21.92M (+273.93%)
What is BioCryst Pharmaceuticals, Inc. TTM EBITDA?
The current TTM EBITDA of BCRX is $77.40M
What is the all-time high TTM EBITDA for BioCryst Pharmaceuticals, Inc.?
BioCryst Pharmaceuticals, Inc. all-time high TTM EBITDA is $77.40M
What is BioCryst Pharmaceuticals, Inc. TTM EBITDA year-on-year change?
Over the past year, BCRX TTM EBITDA has changed by +$116.75M (+296.72%)